A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

NCT03835819 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Pembrolizumab
DRUG: IMGN853

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]